Pemigatinib, a fibroblast growth factor receptor (FGFR) 1-, 2-, and 3-selective inhibitor, has been approved for the treatment of previously treated unresectable BTC with FGFR2 fusion or rearrangement [5–7], which is detected in 10–20% of iCCA patients [7]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.